Eliminating “Sophie’s Choice” Decisions for U.S. Prescription Drugs
After presenting the case of an older adult who had to prioritize treatment of severe tooth pain over medications for high blood pressure, authors write,
After presenting the case of an older adult who had to prioritize treatment of severe tooth pain over medications for high blood pressure, authors write,
Among indications of drugs approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2011–2020, the therapeutic value of
“Programmable [small interfering RNA (siRNA)] therapeutics have demonstrated effectiveness for treating an increasing number of rare conditions,” write authors of a review article. “The approach
“In the age of supply chain shortages, it is imperative that the US pursue resilience and promote public policies to better protect the health of
Based on an analysis of 170 FDA-approved drugs across 455 cancer indications from 2000 to 2022, researchers conclude that a “distinct ultra-orphan designation with greater
Using novel mRNA display screening technology, researchers developed MK-0616, an oral PCSK9 inhibitor that “has the potential to be a highly effective cholesterol lowering therapy
Less clinical benefit and higher drug costs are significant predictors that a manufacturer will use direct-to-consumer advertising in its marketing efforts, a study shows. “Direct-to-consumer
The challenges of maintaining an adequate supply of prescription drugs in the U.S. are many, starting with the numbers: more than 20,000 approved prescription drug
Rebates to the federal government for greater-than-inflation increases in the prices of Medicare Part B drugs would have totaled $3.7 billion had provisions of the
For the 39 brand-name inhalers approved by FDA in 2000 through 2021, manufacturers earned $67.2 billion when primary patents were in effect, a study shows.